Page last updated: 2024-11-04

tegafur and Neutropenia

tegafur has been researched along with Neutropenia in 120 studies

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research Excerpts

ExcerptRelevanceReference
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."9.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan."9.22S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016)
"Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)."9.20Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015)
"S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC)."9.20Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M, 2015)
"We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events."9.20Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015)
"To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)."9.19Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014)
"In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI."9.16Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012)
"We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)."9.16Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012)
"This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer."9.15Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011)
"Gemcitabine and S-1 combination chemotherapy has promising efficacy and good tolerability in patients with advanced biliary tract cancer."9.14Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010)
"This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer."9.09UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."8.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades."7.88S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018)
"We experienced a case of good response in acute respiratory distress syndrome (ARDS) treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma."7.74[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007)
"Grade 3 neutropenia was common (35%)."6.90A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019)
"Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory."6.82Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016)
" Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy."6.72[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."5.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan."5.22S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016)
"We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events."5.20Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015)
"S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC)."5.20Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M, 2015)
"Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)."5.20Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015)
"To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)."5.19Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014)
"We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC)."5.17Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ( Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW, 2013)
"In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI."5.16Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012)
"We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)."5.16Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012)
"This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer."5.15Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011)
"Patients were eligible for the study if they had histologically documented gastric adenocarcinoma previously treated with paclitaxel and cisplatin, age > or = 18 years, Eastern Clinical Oncology Group performance status < or =2, adequate organ function, and no evidence of gastrointestinal obstruction or passage disturbance."5.14Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Lee, SJ; Shim, HJ; Yoon, JY, 2009)
"Gemcitabine and S-1 combination chemotherapy has promising efficacy and good tolerability in patients with advanced biliary tract cancer."5.14Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010)
"This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer."5.09UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."4.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer."4.83[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006)
"Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades."3.88S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018)
"We experienced a case of good response in acute respiratory distress syndrome (ARDS) treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma."3.74[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007)
"Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)."3.69Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997)
"Twenty-five adult patients with adenocarcinoma of unknown primary origin were treated with oral tegafur followed by the combination of cyclophosphamide/adriamycin/cis-diamminedichloroplatinum(II) (CAP) if they failed to respond to tegafur."3.66Sequential chemotherapy for adenocarcinoma of unknown primary. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
"Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled."3.01Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021)
"Grade 3 neutropenia was common (35%)."2.90A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019)
"Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown."2.90Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019)
"Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory."2.82Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016)
"This phase I trial of preoperative S-1 in combination with oxaliplatin and radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis revealed that the recommended dose of oxaliplatin was 60 mg/m(2) weekly."2.80A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015)
"The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy."2.79Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014)
"Patients with gastric cancer with bulky lymph node metastasis along the coeliac artery and its branches and/or PAN metastasis received two or three 28-day cycles of S-1 plus cisplatin, followed by gastrectomy with D2 plus PAN dissection."2.79Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. ( Fukushima, N; Mizusawa, J; Nashimoto, A; Sasako, M; Tanaka, Y; Tsuburaya, A, 2014)
"Paclitaxel was administered intravenously on day 1 at a dose of 120 mg/m(2), and oral S-1 was administered twice a day from days 1 to 7, followed by a 7-day drug-free interval."2.79Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. ( Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y, 2014)
"Cediranib 20 mg/day in combination with cisplatin and S-1 or capecitabine was tolerable, with no new toxicities identified, and showed preliminary evidence of antitumour activity."2.77Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012)
"Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks."2.76Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011)
"Diarrhea was the most common type of nonhematologic toxicity: 3 patients had Grade 3 diarrhea."2.76A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. ( Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K, 2011)
"Paclitaxel (160 mg/m²) was administered by infusion for 3 h on the first day."2.76A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. ( Goto, H; Haruta, J; Ina, K; Iwase, H; Kumada, T; Shimada, M; Shinoda, M; Sugihara, M; Tsuzuki, T, 2011)
" Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle."2.75Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010)
"Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)."2.74Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. ( Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009)
"Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined."2.73A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. ( Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB, 2008)
"He died of brain metastases."2.72[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]. ( Asou, H; Ichinose, Y; Maruyama, R; Okamoto, T; Suemitsu, R; Wataya, H, 2006)
" Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy."2.72[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006)
"Grade 4 neutropenia was observed in one of the 59 patients (1."2.72[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. ( Kawahara, M; Yumine, K, 2006)
"Paclitaxel was administered by intravenous drip infusion at a starting dose (level 1) of 50 mg/m2 on days 1, 8, and 15."2.72[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer]. ( Doki, Y; Fujita, J; Fujiwara, Y; Kan, K; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, K; Yasuda, T, 2006)
"Irinotecan was given intravenously over the course of 90 min on day 1 and S-1 was given orally from days 1 to 14 of a 21-day cycle."2.71Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H, 2003)
" Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps."2.71[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004)
"Grade 4 neutropenia was observed in one of the 59 patients (1."2.70Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. ( Furuse, K; Hasegawa, K; Kawahara, M; Kudoh, S; Matsui, K; Niitani, H; Segawa, Y; Yoshimori, K, 2001)
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."2.69A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000)
"Oral tegafur and I."2.65A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983)
"Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs."2.43[S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006)
"Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support."1.51Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019)
"However, severe neutropenia is often observed (40%) during this therapy."1.48Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer. ( Kawachi, S; Kimura, M; Shinoda, Y; Usami, E; Yoshimura, T, 2018)
"Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC."1.46Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017)
"The chemotherapy regime was 80 mg/m(2) liposome-paclitaxel given on days 1, 8, 15 and 22, combined with S-1 60 mg (body surface area > 1."1.40Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer. ( Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z, 2014)
" The most common adverse events were neutropenia (n = 49, 69."1.38[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012)
"The regimen of nedaplatin combined with tegafur is effective and tolerable for the treatment of advanced esophageal cancer."1.35[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer]. ( Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008)
" Thus, TS-1 and CPT-11 combination therapy has been effective for 17 months, suggesting that it is promising for long-term administration and survival to continue it perseveringly."1.33[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy]. ( Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D, 2006)
"Grade 3 neutropenia was observed, but no other severe toxicities were noted."1.33[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report]. ( Boku, N; Fukutomi, A; Yoshino, T, 2006)
"As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was conducted on an all-case basis."1.33[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--]. ( Ito, K, 2006)

Research

Studies (120)

TimeframeStudies, this research(%)All Research%
pre-19902 (1.67)18.7374
1990's5 (4.17)18.2507
2000's45 (37.50)29.6817
2010's65 (54.17)24.3611
2020's3 (2.50)2.80

Authors

AuthorsStudies
Hirahara, N1
Matsubara, T1
Kaji, S2
Yamamoto, T1
Hyakudomi, R1
Takai, K1
Ishitobi, K1
Uchida, Y1
Tajima, Y1
Kasai, T2
Mori, K1
Kishi, K1
Kaburagi, T1
Hosomi, Y1
Imai, H2
Yamada, Y4
Yomota, M1
Moriguchi, S1
Seike, M1
Minato, K1
Gemma, A3
Tsuchiya, T1
Kamohara, R1
Muraoka, M1
Nagayasu, T1
Saeki, S1
Takenoyama, M1
Suzuki, M2
Inada, K1
Tokunaga, S1
Hayashi, T2
Urabe, S1
Koga, T1
Akamine, S1
Sugio, K1
Fang, M1
Song, T1
Liang, X1
Lv, S1
Li, J3
Xu, H1
Luo, L1
Jia, Y1
Hamada, C1
Okusaka, T3
Ikari, T1
Isayama, H3
Furuse, J4
Ishii, H2
Nakai, Y3
Imai, S2
Okamura, S1
Wang, F1
Fan, QX2
Wang, HH1
Han, DM1
Song, NS1
Lu, H1
Xu, R1
Xu, J1
Denda, T1
Ikejiri, K1
Shen, L2
Toh, Y1
Shimada, K4
Kato, T1
Sakai, K1
Yamamoto, M1
Mishima, H1
Wang, J2
Baba, H4
Winther, SB1
Bjerregaard, JK1
Schonnemann, KR1
Ejlsmark, MW1
Krogh, M1
Jensen, HA1
Pfeiffer, P1
Kawachi, S1
Shinoda, Y1
Kimura, M3
Usami, E1
Yoshimura, T1
Nakachi, K1
Konishi, M1
Ikeda, M2
Saiura, A1
Sugiyama, M2
Sakamoto, H1
Shimamura, T1
Ohta, T1
Motoi, F1
Satoi, S1
Honda, G2
Wada, K1
Shinchi, H1
Matsumoto, I1
Sho, M1
Tsuchida, A1
Unno, M1
Kashiwabara, K1
Semba, H1
Fujii, S2
Tsumura, S1
Shigeyoshi, I1
Misawa, K1
Ito, S1
Ito, Y3
Komori, K1
Abe, T1
Senda, Y1
Kinoshita, T1
Uemura, N1
Natsume, S1
Oshiro, T1
Higaki, E1
Shimizu, Y2
Sugawara, S2
Nakagawa, K2
Yamamoto, N2
Nokihara, H1
Ohe, Y1
Nishio, M1
Takahashi, T1
Goto, K1
Maemondo, M2
Ichinose, Y4
Seto, T2
Sakai, H1
Imamura, F1
Shingyoji, M1
Saka, H2
Inoue, A2
Takeda, K2
Okamoto, I2
Kiura, K1
Morita, S5
Tamura, T1
Koizumi, W4
Nishikawa, K2
Gotoh, M2
Fuse, N1
Sugimoto, N2
Nishina, T2
Amagai, K1
Chin, K1
Niwa, Y1
Tsuji, A5
Imamura, H4
Tsuda, M1
Yasui, H4
Fujii, H1
Yamaguchi, K5
Hironaka, S3
Hyodo, I2
Arai, H1
Iwasa, S1
Boku, N5
Kawahira, M1
Masuishi, T1
Muro, K3
Minashi, K1
Fukuda, N1
Takahari, D2
Nakajima, TE3
Tachihara, M1
Ishimoto, O1
Sakakibara, T1
Usui, K1
Watanabe, H1
Matsubara, N2
Watanabe, K1
Kanazawa, K1
Ishida, T1
Saijo, Y1
Nukiwa, T1
Iwase, H2
Shimada, M2
Tsuzuki, T2
Hirashima, N1
Okeya, M1
Hibino, Y1
Ryuge, N1
Yokoi, M1
Kida, Y1
Kuno, T1
Tanaka, Y3
Kato, B1
Esaki, M1
Urata, N1
Kato, E1
Otsuka, H1
Fujii, T1
Toh, U1
Iwakuma, N1
Takahashi, R1
Mishima, M1
Takenaka, M1
Kakuma, T1
Tanaka, M2
Shirouzu, K1
Park, SR1
Hong, YS2
Lim, HS1
Seong, MW1
Kong, SY1
Kim, SY1
Park, YI1
Jung, KH1
Takahara, N1
Sasaki, T6
Hamada, T2
Uchino, R1
Mizuno, S1
Miyabayashi, K1
Kogure, H2
Sasahira, N2
Hirano, K2
Ijichi, H1
Tateishi, K1
Tada, M2
Koike, K1
Sunaga, T1
Suzuki, S1
Kogo, M1
Kurihara, T1
Koike, N1
Harada, N1
Kiuchi, Y1
Kaira, K3
Tomizawa, Y2
Yoshino, R1
Yoshii, A1
Matsuura, M1
Iwasaki, Y2
Koga, Y1
Ono, A1
Nishioka, M1
Kamide, Y1
Hisada, T3
Ishizuka, T3
Shirai, K1
Ebara, T1
Saitoh, J1
Nakano, T1
Sunaga, N3
Chen, L1
Chen, Q1
Zhuang, Z1
Zhang, Y1
Tao, J1
Shen, X1
Chen, Z1
Zhu, M1
Wang, H1
Sato, D1
Kogashiwa, Y1
Tsukahara, K2
Yamauchi, K1
Kohno, N2
Tsuburaya, A2
Mizusawa, J1
Fukushima, N1
Nashimoto, A1
Sasako, M1
Ohue, M1
Hamaguchi, T2
Sakai, D2
Noura, S1
Kinugasa, Y1
Fujita, S1
Shimada, Y3
Saito, N1
Moriya, Y1
Lee, KW2
Kim, YJ2
Lee, KH1
Han, SW1
Kim, TY3
Oh, DY3
Im, SA2
Bang, YJ3
Choi, IS3
Kim, JH5
Yoshida, K3
Kobayashi, M1
Yoshino, S1
Takahashi, M1
Takiguchi, N1
Tanabe, K2
Takahashi, N1
Tatsumoto, N1
Hara, A1
Fukushima, R1
Nozaki, I1
Kojima, H1
Miyashita, Y1
Oba, K1
Buyse, M1
Sakamoto, J3
Zheng, Y2
Fang, W1
Mao, C1
Qian, J1
Zhao, P1
Zhang, X1
Jiang, H1
Xu, N1
Kobayashi, S2
Nagano, H2
Eguchi, H1
Hatano, E1
Kanai, M2
Seo, S1
Taura, K1
Fujiwara, Y2
Ajiki, T1
Takemura, S1
Kubo, S1
Yanagimoto, H1
Toyokawa, H1
Terajima, H1
Ioka, T1
Ishiwatari, H1
Yoshida, M1
Ono, M1
Sato, T4
Miyanishi, K2
Sato, Y3
Takimoto, R2
Kobune, M2
Kato, J2
Mizushima, T1
Tamagawa, H1
Matsuda, C1
Murata, K1
Fukunaga, M1
Ota, H1
Hasegawa, J1
Tsujie, M1
Fukuzaki, T1
Hata, T1
Takemasa, I1
Yamamoto, H1
Sekimoto, M1
Nezu, R1
Doki, Y2
Mori, M3
Nakamura, Y1
Fukuda, M1
Kitazaki, T1
Nagashima, S1
Takatani, H1
Nakano, H1
Nakatomi, K1
Ikeda, T1
Yamaguchi, H1
Tsukamoto, K1
Oka, M1
Kohno, S1
Takashima, T1
Mukai, H1
Hara, F1
Saito, T1
Takano, T1
Park, Y1
Toyama, T1
Hozumi, Y1
Tsurutani, J1
Imoto, S1
Watanabe, T1
Sagara, Y1
Nishimura, R1
Shimozuma, K1
Ohashi, Y2
Moriwaki, T1
Komatsu, Y4
Machida, N1
Bando, H1
Esaki, T1
Emi, Y3
Sekikawa, T1
Matsumoto, S3
Takeuchi, M1
Miyamoto, Y2
Tanioka, H1
Maekawa, S1
Kawanaka, H1
Kitazono, M1
Oki, E3
Murakami, H1
Ogata, Y1
Saeki, H1
Shimokawa, M1
Natsugoe, S2
Akagi, Y1
Maehara, Y4
Abdel-Rahman, O1
ElHalawani, H1
Essam-Eldin, S1
Kurata, M1
Okuda, Y1
Sakamoto, K1
Karasawa, K1
Chang, T1
Egawa, N1
Kamisawa, T1
Omuro, Y1
Tsuruta, K1
Tanahashi, T1
Okumura, N1
Matsuhashi, N1
Yeo, W1
Lam, KO1
Law, AL1
Lee, CC1
Chiang, CL1
Au, KH1
Mo, FK1
So, TH1
Lam, KC1
Ng, WT1
Li, L1
Arima, S1
Shimizu, K3
Okamoto, T2
Toki, M1
Suzuki, Y1
Okano, N1
Naruge, D1
Kawai, K1
Kobayashi, T1
Kasuga, A1
Kitamura, H1
Takasu, A1
Nagashima, F1
Yanagitani, N2
Aoki, H1
Kawata, T1
Utsugi, M2
Wang, R1
Lu, P1
Zhao, YF1
Lu, TY1
Han, JW1
Wang, JS1
Luo, SX1
Lu, SP1
Wang, GJ1
Geng, L1
Zhang, MZ1
Ma, ZY1
Song, M1
Wu, XA1
Chen, XB1
Jiao, ZM1
Wang, RL1
Zang, DY1
Yang, DH1
Kim, MJ2
Jang, KM1
Hwang, SW1
Yoo, KS1
Han, T1
Kim, HY1
Kim, HJ1
Kwon, JH1
Song, HH1
Park, S1
Jung, JY1
Kim, HS2
Surmont, V1
Aerts, JG1
Pouw, E1
Tan, KY1
Vernhout, R1
Gras, J1
Salomé, J1
Pronk, T1
Schmitz, PI1
Hoogsteden, H1
van Klaveren, RJ1
Lee, SJ1
Cho, SH1
Yoon, JY1
Hwang, JE1
Bae, WK1
Shim, HJ1
Chung, IJ1
Park, I1
Lee, JL4
Ryu, MH2
Chang, HM2
Kim, TW4
Sym, SJ1
Lee, SS3
Jang, G1
Yoo, C1
Bae, KS1
Kang, YK2
Cha, Y1
Yoon, SY1
Choi, IK1
Oh, SC1
Kim, CD1
Kim, JS1
Kim, YH1
Iijima, H1
Tsurumaki, H1
Saito, R1
Togawa, O1
Toda, N1
Yasuda, I1
Hasebe, O1
Maetani, I1
Tsujino, T1
Omata, M1
Akiya, T1
Sato, A1
Sakuyama, T1
Sasaki, E1
Tomidokoro, T1
Fujimori, M1
Kikuchi, Y1
Mine, T1
Kurihara, M1
Takiguchi, Y1
Tada, Y1
Kudoh, S3
Hino, M1
Yoshimori, K2
Yoshimura, A1
Nagao, K1
Niitani, H2
Yokoyama, T1
Tokuhara, H1
Egawa, T1
Hashimoto, O1
Seki, H1
Koyanagi, K1
Bessho, T1
Takayama, T1
Sagawa, T1
Takahashi, Y2
Ohnuma, H1
Okubo, S1
Shintani, N1
Tanaka, S1
Kida, M1
Ohta, H1
Hirata, K2
Niitsu, Y1
Bin, Q1
Liao, C1
Cao, Y1
Gao, F1
Yanagihara, K1
Yoshimura, K1
Niimi, M1
Yasuda, H1
Nishimura, T1
Ishiguro, H1
Kitano, T1
Misawa, A1
Tada, H1
Teramukai, S2
Mio, T1
Fukushima, M2
Park, JH1
Yoon, SN1
Lim, SB1
Yu, CS1
Jang, SJ1
Lee, JS2
Kim, JC1
Nakayama, M1
Hayakawa, K2
Okamoto, M1
Niibe, Y1
Ishiyama, H1
Kotani, S1
Ozawa, H1
Hatate, K1
Onosato, W1
Naito, M1
Nakamura, T1
Ihara, A1
Okayasu, I1
Yamashita, K1
Watanabe, M2
Nagase, T1
Kanai, T1
Nakagawa, M1
Kumamoto, Y1
Wada, O1
Honda, T1
Hoshino, G1
Atsukawa, K1
Sakaguchi, T1
Shiba, T1
Nonaka, T2
Imajyo, K1
Ogawa, Y1
Chon, HJ1
Rha, SY1
Park, HS1
Shin, SJ1
Roh, JK1
Noh, SH1
Chung, HC1
Jeung, HC1
Nagai, H1
Takamaru, N1
Ohe, G1
Uchida, D1
Tamatani, T1
Fujisawa, K1
Iwamoto, S2
Yuki, S3
Sogabe, S2
Fukushima, H2
Iwanaga, I2
Kudo, M3
Tateyama, M3
Meguro, T2
Uebayashi, M1
Saga, A1
Sakata, Y3
Asaka, M2
Ina, K1
Sugihara, M1
Haruta, J1
Shinoda, M1
Kumada, T1
Goto, H1
Ueno, H1
Yamao, K1
Funakoshi, A1
Ohkawa, S1
Yokosuka, O1
Tanaka, K1
Moriyasu, F1
Nakamori, S2
Nakayama, N1
Tanabe, S1
Higuchi, K1
Nishimura, K1
Takagi, S1
Azuma, M1
Ae, T1
Ishido, K1
Nakatani, K1
Naruke, A1
Katada, C1
Satoh, T1
Hayashi, H1
Taku, K1
Shi, X1
Brown, KH1
Yamanaka, T2
Katakami, N1
Sawa, T1
Nishimura, Y1
Fukuoka, M1
Nakatsumi, H1
Kobayashi, Y1
Nakamura, M1
Hatanaka, K1
Miyagishima, T1
Munakata, M2
Kang, MJ1
Ahn, S1
Park, DH1
Seo, DW1
Lee, SK1
Kim, MH1
Kunisaki, C1
Ono, HA1
Hasegawa, S1
Oshima, T1
Tokuhisa, M1
Izumisawa, Y1
Takagawa, R1
Kimura, J1
Kosaka, T1
Makino, H1
Akiyama, H1
Endo, I1
Kimura, Y2
Yano, H1
Fujitani, K2
Imano, M2
Tokunaga, Y1
Matsuoka, M1
Kurokawa, Y1
Shimokawa, T2
Takiuchi, H3
Tsujinaka, T1
Furukawa, H2
Zhou, Y1
Huang, J1
Yang, L1
Chi, Y1
Qu, T1
Lü, X1
Wang, JW1
Nishino, H1
Shinozaki, T1
Ishikawa, K1
Tanaka, H1
Ichimura, K1
Goto, A2
Arai, T1
Ura, T1
Shirao, K2
Tujie, M1
Maruhashi, S1
Miyamoto, A1
Dono, K1
Umeshita, K1
Sakon, M1
Monden, M2
Hino, S1
Shintani, S1
Hara, S1
Hamakawa, H1
Hirakawa, K2
Nakata, B2
Saji, S1
Saeki, T2
Takashima, S2
Sano, M2
Horikoshi, N2
Miura, S1
Shimizu, S1
Morimoto, K2
Taguchi, T2
Nakazawa, M2
Ohnishi, T1
Chisoku, H1
Katagiri, W1
Doi, T1
Takase, T1
Yui, S1
Miwa, Y1
Fukuda, Y1
Kishino, M1
Yura, Y1
Fujita, J1
Kan, K1
Takiguchi, S1
Miyata, H1
Yasuda, T1
Ito, K1
Takahashi, I2
Kakeji, Y2
Tokunaga, E1
Ushiro, S1
Wataya, H2
Asou, H1
Maruyama, R1
Suemitsu, R1
Ishida, H2
Akita, H1
Watanabe, Y1
Nakaguchi, K1
Kabuto, T1
Yoshioka, K1
Shitara, K1
Kudou, T1
Ohtsu, A1
Wada, Y1
Ukon, K1
Hihara, J1
Egashira, A1
Morita, M1
Eguchi, T1
Fujii, M1
Tahara, M1
Yumine, K1
Kawahara, M2
Kawamura, S1
Yamagishi, D1
Tei, M1
Sumi, Y1
Shimada, E1
Okumura, S1
Yoshino, T1
Fukutomi, A1
Mitachi, Y1
Yamamitsu, S1
Takeuchi, T1
Shirasaka, T1
Rivera, F1
Vega-Villegas, ME1
López-Brea, MF1
García-Castaño, A1
de Juan, A1
Ramos, FJ1
Collado, A1
Galdós, P1
Rubio, A1
del Valle, A1
Rama, J1
Mayorga, M1
Sanz-Ortiz, J1
Ishiwata, R1
Nagai, Y1
Kang, HJ1
Sohn, HJ1
Kim, H1
Hanada, N1
Kusano, S1
Hori, K1
Momi, H1
Kim, HG1
Oh, SY1
Lee, SH1
Kim, DW1
Kim, SW1
Heo, DS1
Yoon, YB1
Goto, M1
Imamoto, H1
Narahara, H1
Nakajo, A1
Hokita, S1
Ishigami, S1
Miyazono, F1
Etoh, T1
Hamanoue, M1
Maenohara, S1
Iwashita, T1
Komatsu, H1
Satoh, K1
Aridome, K1
Nakano, S1
Aikou, T1
Bedikian, AY2
Stroehlein, J1
Korinek, J1
Karlin, D1
Bodey, GP2
Valdivieso, M1
Burgess, MA1
Scherrer, R1
Geissler, K1
Kyrle, PA1
Gisslinger, H1
Jäger, U1
Bettelheim, P1
Laczika, K1
Locker, G1
Scholten, C1
Sillaber, C1
Martin, M1
Casado, A1
López-Martin, JA1
Rodriguez-Lescure, A1
Nieto, Y1
Ayala, F1
Diaz-Rubio, E2
González-Larriba, JL1
Garcia Carbonero, I1
Sastre Valera, J1
Perez Segura, P1
Toge, T1
Aoyama, H1
Ota, J1
Noguchi, S1
Inuyama, Y1
Kida, A1
Tsukuda, M1
Satake, B1
Childs, HA1
Spencer, SA1
Raben, D1
Bonner, JA1
Newsome, J1
Robert, F1
Gregory, RK1
Johnston, SR1
Smith, IE1
Miles, D1
Furuse, K1
Segawa, Y1
Matsui, K1
Hasegawa, K1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916]Phase 242 participants (Actual)Interventional2015-07-31Completed
Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291]Phase 230 participants (Anticipated)Interventional2013-12-31Not yet recruiting
Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096]Phase 235 participants (Anticipated)Interventional2017-02-01Recruiting
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552]Phase 30 participants (Actual)Interventional2016-03-31Withdrawn
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer[NCT01291615]Phase 16 participants (Actual)Interventional2010-12-31Completed
Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074]Phase 248 participants (Anticipated)Interventional2016-07-22Recruiting
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703]Phase 238 participants (Actual)Interventional2005-08-31Completed
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790]Phase 253 participants (Actual)Interventional2007-10-31Completed
PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698]Phase 262 participants (Anticipated)Interventional2023-01-31Recruiting
Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer[NCT01375972]Phase 292 participants (Actual)Interventional2008-03-31Completed
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449]Phase 3338 participants (Actual)Interventional2012-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

9 reviews available for tegafur and Neutropenia

ArticleYear
S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines.
    Expert opinion on drug safety, 2016, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials,

2016
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans

2011
[S-1 for gastric cancer-S-1 monotherapy and its progress].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy

2006
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic

2006
[S-1 as a single agent for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2006
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials

2006
[Combination therapy with S-1 and CDDP for head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinom

2006
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, N

2006
[Clinical benefit of S-1 in metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal,

2006

Trials

79 trials available for tegafur and Neutropenia

ArticleYear
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    BMC cancer, 2021, Oct-01, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2021
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
    International journal of clinical oncology, 2020, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat

2020
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    BMC cancer, 2020, Dec-04, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Non-Small-Cell Lung;

2020
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2017
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2017, Jun-23, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations;

2017
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
    Cancer science, 2017, Volume: 108, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col

2017
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    Journal of gastroenterology, 2019, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1

2019
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
    International journal of clinical oncology, 2019, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dis

2019
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
    Cancer science, 2019, Volume: 110, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons

2019
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 81, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

2013
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
    Oncology, 2013, Volume: 84, Issue:6

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy;

2013
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
    Breast cancer (Tokyo, Japan), 2015, Volume: 22, Issue:4

    Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

2015
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydro

2013
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dr

2013
Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma.
    Chemotherapy, 2013, Volume: 59, Issue:4

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Sch

2013
Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    The British journal of surgery, 2014, Volume: 101, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2014
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A

2015
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deo

2014
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2014
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3

    Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian Peo

2014
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidin

2014
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo

2015
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
    Oncology, 2015, Volume: 89, Issue:3

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2015
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Chemotherapy, 2016, Volume: 61, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dr

2016
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease

2016
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Fre

2016
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    International journal of clinical oncology, 2016, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2016
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor

2015
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Cancer science, 2016, Volume: 107, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com

2016
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Anticancer research, 2017, Volume: 37, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co

2017
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
    Anti-cancer drugs, 2008, Volume: 19, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci

2008
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 66, Issue:3

    Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small

2009
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2009
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat

2010
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatig

2010
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell

2010
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine;

2010
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:6

    Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema

2010
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3

    Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; D

2010
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen

2010
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease

2010
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2011
Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administr

2010
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2011
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Su

2011
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2011
A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviva

2011
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad

2011
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Admi

2012
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl

2012
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora

2011
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
    Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:6

    Topics: Aged; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2012
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

2013
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
    International journal of clinical oncology, 2003, Volume: 8, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dru

2003
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; D

2004
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:3

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols;

2004
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat

2004
[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug

2006
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
    Oncology reports, 2006, Volume: 15, Issue:4

    Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under

2006
[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dr

2006
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio

2006
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot

2006
[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl

2006
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C

2006
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy

2006
Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car

2007
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:5

    Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea;

2008
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2008
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free

2008
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr

2008
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 1983, Volume: 6, Issue:2

    Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections,

1983
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C

1997
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati

1998
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:8

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce

1998
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2000, Jul-01, Volume: 47, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia

2000
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:10 Suppl 9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2000
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
    British journal of cancer, 2001, Sep-28, Volume: 85, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung;

2001

Other Studies

32 other studies available for tegafur and Neutropenia

ArticleYear
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
    British journal of cancer, 2017, Jun-06, Volume: 116, Issue:12

    Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;

2017
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho

2018
Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer.
    Die Pharmazie, 2018, 03-05, Volume: 73, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H

2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
    International journal of clinical oncology, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Papillary; Carcino

2018
Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.
    Cancer investigation, 2018, Volume: 36, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L

2018
[The Case of a Patient with Gastric Cancer Who Showed No Neutropenia Only When Using the Generic S-1 Adjuvant Chemotherapy Formulation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Drugs, Generic; Fe

2018
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
    BMC cancer, 2019, Jul-03, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin;

2019
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
    European journal of cancer care, 2014, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother

2014
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug A

2014
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2017, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Chemotherap

2017
[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo

2009
[The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dise

2009
[Analysis of four patients with advanced gastric cancer undergoing gastrectomy after pre-operative combination chemotherapy using docetaxel, cisplatin and S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2010
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2011
[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2012
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Co

2002
[A case of advanced maxillary carcinoma with cervical lymph node metastases showing a complete response to the combination therapy of CDDP, TS-1 and radiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva

2004
[Preoperative chemotherapy with TS-1 and low dose cisplatin for oral squamous cell carcinoma patients--a preliminary study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2005
[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capsules; Drug Administration Schedule; Drug Combinations; Drug Mon

2006
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop

2006
[24 hour infusion of CPT-11/oral UFT/LV].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2006
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Dr

2006
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; D

2006
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine;

2006
Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H

2006
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.
    British journal of cancer, 2007, Jul-02, Volume: 97, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans;

2007
[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic;

2007
Sequential chemotherapy for adenocarcinoma of unknown primary.
    American journal of clinical oncology, 1983, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1983
Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).
    Annals of hematology, 1993, Volume: 66, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Cell

1993
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea

1997